Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gammopathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Gammopathy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-022693-14 Sponsor Protocol Number: METc2010.214 Start Date*: 2010-09-24
    Sponsor Name:university medical centre groningen
    Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)
    Medical condition: Monoclonal Gammopathy of Undetermined significance
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027522 MGUS LLT
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003865-11 Sponsor Protocol Number: NEOD001-CL002 Start Date*: 2015-11-27
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai...
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004318-14 Sponsor Protocol Number: NEOD001-201 Start Date*: 2016-06-13
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005856-12 Sponsor Protocol Number: 20221 Start Date*: 2022-01-31
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Monoclonal gammopathies of renal significance (MGRS) in Finland
    Medical condition: Rare renal diseases linked to monoclonal gammopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020072-33 Sponsor Protocol Number: BVD-CLEM 01-10 Start Date*: 2011-02-10
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma
    Medical condition: Relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051381 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024156-28 Sponsor Protocol Number: CACZ885DDE03T Start Date*: 2011-05-16
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome
    Medical condition: Schnitzler syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10062908 Schnitzler's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021166-30 Sponsor Protocol Number: 2010-SS-Canakinumab Start Date*: 2010-11-25
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Efficacy and safety of canakinumab in Schnitzler syndrome
    Medical condition: Schnitzler syndrome is an acquired autoinflammatory syndrome characterized by urticaria and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain and lymphade...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003835-20 Sponsor Protocol Number: ALN-TTRSC-004 Start Date*: 2014-11-26
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyl...
    Medical condition: Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10016202 Familial amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002637-15 Sponsor Protocol Number: APL2-C3G-204 Start Date*: 2020-12-22
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF POST-TRANSPLANT RECURRENCE OF C3G OR IC‑MPGN
    Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001458-24 Sponsor Protocol Number: ALN-TTR02-011 Start Date*: 2019-09-19
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (...
    Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) BG (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004280-32 Sponsor Protocol Number: AG10-301 Start Date*: 2019-05-10
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
    Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004290-97 Sponsor Protocol Number: ACCILTRA1 Start Date*: 2008-12-19
    Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
    Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle...
    Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004998-53 Sponsor Protocol Number: OMB116024 Start Date*: 2013-02-05
    Sponsor Name:National and Kapodistrian University of Athens
    Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia.
    Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000009-25 Sponsor Protocol Number: 19PH226 Start Date*: 2021-04-12
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study
    Medical condition: Anti-MAG neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066137 Anti-MAG neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001992-17 Sponsor Protocol Number: APHP210369 Start Date*: 2021-08-16
    Sponsor Name:Assistance Publique - Hôpitaux de Paris / DRCI
    Full Title: Isatuximab in type I cryoglobulinaemia: A prospective pilot study / ICE STUDY
    Medical condition: Type I cryoglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10011475 Cryoglobulinemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002655-33 Sponsor Protocol Number: IEO S303/306 Start Date*: 2006-07-25
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Safety evaluation of the i.v. administration of Visipaque in patients with myeloma or monoclonal gammopathy
    Medical condition: multiple myeloma, Waldenstrom disease o MGUS and lung cancer patients (control group
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002585-33 Sponsor Protocol Number: PETAL Start Date*: 2023-01-19
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT)
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005557-73 Sponsor Protocol Number: I10E-1302 Start Date*: 2014-10-21
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002639-48 Sponsor Protocol Number: 54767414AMY2009 Start Date*: 2022-07-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
    Medical condition: Amyloid Light Chain Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000037-14 Sponsor Protocol Number: NEOD001-301 Start Date*: 2021-09-01
    Sponsor Name:Prothena Biosciences Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ...
    Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:55:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA